ReviewThe lancet. HIV2022
Two-drug regimens for HIV treatment.
Review in The lancet. HIV, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07678268 (Effectiveness and Safety of Darunavir/Cobicistat Plus Lamivudine Compared With Darunavir/Cobicistat Plus Tenofovir Alafenamide/Emtricitabine in Virologically Suppressed People Living With HIV at 24 and 48 Weeks of Follow-up), which is not on this map. Cited by 41 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Effectiveness and Safety of Darunavir/Cobicistat Plus Lamivudine Compared With Darunavir/Cobicistat Plus Tenofovir Alafenamide/Emtricitabine in Virologically Suppressed People Living With HIV at 24 and 48 Weeks of Follow-up
Who cites it
41 citing papers in PubMed, 1 synthesis or guideline pooled it, 66 citations in OpenAlex.
- Efficacy and safety of doravirine/islatravir for the treatment of HIV-1: a systematic review and meta-analysis of randomized controlled trials with GRADE assessment.European journal of clinical pharmacology · 2026Pooled it
- Phase 2 Trial of Long-Acting Cabotegravir and VRC07-523LS for Viral Suppression in Adults With HIV-1: ACTG A5357.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2026Trial
- Efficacy and Safety of DRG/3TC for Prophylaxis of HIV Perinatal Transmission: A Pilot Study (PREGNANCY).Open forum infectious diseases · 2024Trial
- Dolutegravir/Lamivudine Is Noninferior to Continuing Dolutegravir- and Non-Dolutegravir-Based Triple-Drug Antiretroviral Therapy in Virologically Suppressed People With Human Immunodeficiency Virus: DUALING Prospective Nationwide Matched Cohort Study.Open forum infectious diseases · 2024Trial
- Doravirine/Islatravir: First Approval.Drugs · 2026Article
- Long-Acting Cabotegravir/Rilpivirine Reduces Immune-Activation and -Senescence in People With HIV With CMV Co-Infection.Immunology · 2026Article
- Real-world clinical and laboratory changes after switching to two-drug regimen in HIV-suppressed individuals: 48 weeks and beyond.HIV medicine · 2026Article
- Drug combination treatment as a strategy for inhibiting human adenovirus replication.Antiviral research · 2026Article
- "It's Our Superpower": A Mixed-Methods Study to Understand Motivation and Capabilities for HIV Management Among African American/Black and Latine Emerging Adults Living With HIV.AIDS and behavior · 2026Article
- Perinatal outcomes associated with antiretroviral therapy for pregnant women living with HIV: an umbrella review.EClinicalMedicine · 2026Review
- IL-18 and MIG increase one year after transition to dolutegravir-based dual therapy despite sustained viral suppression.Frontiers in immunology · 2026Article
- DABPU-DE targeting host adipose triglyceride lipase provides broad-spectrum anti-coronavirus effectsFrontiers in pharmacology · 2026Article
- Forecasting drug resistant HIV protease evolution.PLoS computational biology · 2026Article
- PROs Assessment in Dual (Either Oral or Injectable) Antiretroviral Regimen in People with HIV: A Narrative Review.Viruses · 2025Review
- Association Between Medicaid Prescription Drug Caps And Antiretroviral Adherence Among People Living With HIV.Health affairs (Project Hope) · 2025Article
- Antiretroviral Therapy Changes for Medicare Beneficiaries With HIV Transitioning to Long-Term Care.JAMA network open · 2025Article
- A Quality Improvement Pilot to Increase Hepatitis B Screening and Optimize Patient Selection for the Switch to Two-Drug Antiretroviral Regimens in People With HIV.Open forum infectious diseases · 2025Article
- Positive allosteric modulation of emodepside sensitive Brugia malayi SLO-1F and Onchocerca volvulus SLO-1A potassium channels by GoSlo-SR-5-69.PLoS pathogens · 2025Article
- Frailty, Latent Health Profiles, and Antiretroviral Therapy: Predicting Success of Skilled Nursing Facility Care in an HIV Population.Journal of the American Medical Directors Association · 2025Article
- Dolutegravir plus lamivudine downregulates cellular stress responses vs. three-drug HIV regimens.AIDS (London, England) · 2025Article
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
8 authors at 7 institutions in 4 countries.
Funding
Abstract
Combination therapy with three antiretroviral agents has been integral to successful HIV-1 treatment since 1996. Although the efficacy, adverse effects, and toxicities of contemporary three-drug regimens have improved, even the newest therapies have potential adverse effects. The use of two-drug regimens is one way to reduce lifetime exposure to antiretroviral drugs while maintaining the benefits of viral suppression. Multiple large, randomised trials have shown the virological non-inferiority of certain two-drug regimens versus three-drug comparators, including adverse effect differences that reflect known profiles of the antiretroviral drugs in the respective regimens. Two-drug combinations are now recommended in treatment guidelines and include the first long-acting antiretroviral regimen for the treatment of HIV-1. Recommended two-drug regimens differ in their risks for, and factors associated with, virological failure and emergent resistance. The tolerability, safety, metabolic profiles, and drug interactions of two-drug regimens also vary by the constituent drugs. No current two-drug regimen is recommended for people with chronic hepatitis B virus as none include tenofovir. Two-drug regimens have increased options for individualised care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.